和元生物收盘上涨1.61%，最新市净率2.12，总市值36.87亿元

Company Overview - He Yuan Bio is a biotechnology company focused on gene therapy, providing CRO services for basic research and CDMO services for drug development [1] - The company offers products including gene therapy CRO, gene therapy CDMO, biological agents, and reagents [1] Financial Performance - For the fiscal year 2024, He Yuan Bio reported revenue of 248 million yuan, representing a year-on-year increase of 21.16% [1] - The net profit for the same period was -321.81 million yuan, showing a year-on-year decline of 151.54% [1] - The gross profit margin was reported at -37.81% [1] Shareholder Information - As of March 31, 2025, the number of shareholders for He Yuan Bio was 12,181, a decrease of 122 from the previous count [1] - The average market value of shares held by each shareholder was 352,800 yuan, with an average holding of 27,600 shares [1] Market Valuation - He Yuan Bio's closing stock price was 5.68 yuan, with a market capitalization of 3.687 billion yuan and a price-to-book ratio of 2.12 [1] - The company's PE (TTM) ratio was reported at -11.46, while the industry average PE (TTM) was 45.89 [2]